Halozyme Therapeutics (HALO) vs Immunovant (IMVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immunovant (IMVT) has outperformed Halozyme Therapeutics (HALO) over the past year, gaining 88.2% versus a gain of 68.5%. Over five years, IMVT leads with a +247.0% price change compared with +190.9% for HALO. Halozyme Therapeutics is the larger company by market cap ($12.68 billion vs $6.28 billion), about 2.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HALO | IMVT |
|---|---|---|
| Share price | $111.68 | $30.40 |
| Market cap | $12.68B | $6.28B |
| 1-day change | +1.68% | +0.46% |
| YTD return | +63.21% | +19.04% |
| 1-year return | +68.47% | +88.24% |
| 5-year return | +190.89% | +247.02% |
| P/E ratio (TTM) | 32.65 | — |
| Forward P/E | 10.50 | — |
| EPS (TTM) | $3.42 | $-2.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.40B | — |
| Revenue growth (YoY) | +37.55% | — |
| Net income (latest FY) | $316.89M | $-505.61M |
| Gross margin | 83.62% | — |
| Operating margin | 33.58% | — |
| Net margin | 22.69% | — |
| 52-week high | $116.85 | $45.42 |
| 52-week low | $61.23 | $16.60 |
| Distance from 52-week high | -4.42% | -33.07% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -10.85% | +60.79% |
| Average volume | 2.18M | 1.24M |
| Shares outstanding | 113.50M | 206.55M |
| Employees | 423 | 315 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Halozyme Therapeutics is about 2.0 times larger than Immunovant by market value ($12.68B vs $6.28B).
- IMVT has outperformed HALO by 19.8 percentage points over the past year.
About Halozyme Therapeutics
HALO stock →Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 423 employees
About Immunovant
IMVT stock →Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees
HALO vs IMVT FAQ
Which is bigger, Halozyme Therapeutics or Immunovant?
Halozyme Therapeutics (HALO) is larger, with a market capitalization of $12.68B compared with $6.28B for Immunovant (IMVT).
Which stock has performed better over the past year, HALO or IMVT?
IMVT returned +88.24% over the past 12 months, compared with +68.47% for HALO (price return, excluding dividends). Past performance does not predict future results.
Are Halozyme Therapeutics and Immunovant in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.